Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Johnson & Johnson | CAPLYTA (Lumateperone) - (Study 501) | Major depressive disorder (MDD) | Phase 3 | Data Released | Oral | Psychiatric |
| Johnson & Johnson | ARX788 (ACE-Breast-02) | HER2-positive metastatic breast cancer | Phase 3 | intravenous | Oncology | |
| Johnson & Johnson | CAPLYTA (Lumateperone) ITI-007-201 | Agitation in patients with dementia | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| Johnson & Johnson | XARELTO (rivaroxaban) | Coronary Artery Disease or Peripheral Artery Disease | Phase 3 | Oral | Cardiology | |
| Johnson & Johnson | CAPLYTA (Lumateperone) - Monotherapy (Study 401) | Bipolar depression | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| Johnson & Johnson | Talacotuzumab | Acute myeloid leukemia (AML) | Phase 3 | Intravenous | Oncology | |
| Johnson & Johnson | Milvexian - (Librexia ACS) | Acute coronary syndromes | Phase 3 | Trial Discontinued | Oral | Cardiology |
| Johnson & Johnson | TECVAYLI (teclistamab-cqyv) - (MajesTEC-9) | Multiple myeloma | Phase 3 | Data Released | Subcutaneous | Oncology |
